Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2022;2453:61–77. doi: 10.1007/978-1-0716-2115-8_4

Immunoglobulin/T-Cell Receptor Gene Rearrangement Analysis Using RNA-Seq.

Vincent H J van der Velden, Lorenz Bastian, Monika Brüggemann, Alina M Hartmann, Nikos Darzentas
PMCID: PMC9761498  PMID: 35622320

Abstract

Identification of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements in acute lymphoblastic leukemia (ALL) patients at initial presentation are crucial for monitoring of minimal residual disease (MRD) during subsequent follow-up and thereby for appropriate risk-group stratification. Here we describe how RNA-Seq data can be generated and subsequently analyzed with ARResT/Interrogate to identify possible MRD markers. In addition to the procedures, possible pitfalls will be discussed. Similar strategies can be employed for other lymphoid malignancies, such as lymphoma and myeloma.

Full text of this article can be found in Bookshelf.

References

  1. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E et al (2016) Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group. J Clin Oncol 34:2591–2601 doi: 10.1200/JCO.2015.64.6364. [DOI] [PubMed]
  2. Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A et al (2021) Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the Interfant-06 protocol. J Clin Oncol 39:652–662 doi: 10.1200/JCO.20.02333. [DOI] [PMC free article] [PubMed]
  3. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S et al (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22:771–782 doi: 10.1038/leu.2008.5. [DOI] [PubMed]
  4. Van Dongen JJM, van der Velden VHJ, Brüggemann M, Orfao A (2015) Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125:3996–4009 doi: 10.1182/blood-2015-03-580027. [DOI] [PMC free article] [PubMed]
  5. Van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grümayer ER et al (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604–611 doi: 10.1038/sj.leu.2404586. [DOI] [PubMed]
  6. Van der Velden VHJ, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al (2007) Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21:706–713 doi: 10.1038/sj.leu.2404535. [DOI] [PubMed]
  7. van der Velden VHJ, van Dongen JJM (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 538:115–150 doi: 10.1007/978-1-59745-418-6_7. [DOI] [PubMed]
  8. Brüggemann M, Kotrova M, Knecht H, Bartram J, Boudjogrha M, Bystry V et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33:2241–2253 doi: 10.1038/s41375-019-0496-7. [DOI] [PMC free article] [PubMed]
  9. Bastian L, Schroeder MP, Eckert C, Schlee C, Tanchez JO, Kampf S et al (2019) PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia 33:1895–1909 doi: 10.1038/s41375-019-0430-z. [DOI] [PubMed]
  10. Li Z, Jiang N, Lim EH, Chin WHN, Lu Y, Chiew KH et al (2020) Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq. Leukemia 34:2418–2429 doi: 10.1038/s41375-020-0774-4. [DOI] [PubMed]
  11. Bueno C, Ballerini P, Varela I, Menendez P, Bashford-Rogers R (2020) Shared D-J rearrangements reveal cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL. Blood 136:1108–1111 doi: 10.1182/blood.2020006604. [DOI] [PubMed]
  12. Abdo C, Thonier F, Simonin M, Kaltenbach S, Valduga J, Petit A et al (2020) Caution encouraged in next-generation sequencing immunogenetic analyses in acute lymphoblastic leukemia. Blood 136:1105–1107 doi: 10.1182/blood.2020005613. [DOI] [PubMed]
  13. Van der Velden VHJ, Brüggemann M, Cazzaniga G, Scheijen B, Tops B, Trka J et al (2021) Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS working group study. Leukemia 35:924–928 doi: 10.1038/s41375-021-01154-z. [DOI] [PMC free article] [PubMed]
  14. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M et al (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7:3 doi: 10.1186/1471-2199-7-3. [DOI] [PMC free article] [PubMed]
  15. Ewels P, Magnusson M, Lundin S, Kaller M (2016) MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32:3047–3048 doi: 10.1093/bioinformatics/btw354. [DOI] [PMC free article] [PubMed]
  16. Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Grioni A et al (2017) ARResT/interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics 33:435–437 doi: 10.1093/bioinformatics/btw634. [DOI] [PubMed]
  17. Knecht H, Reigl T, Kotrova M, Appelt F, Stewart P, Bystry V et al (2019) Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33:2254–2265 doi: 10.1038/s41375-019-0499-4. [DOI] [PMC free article] [PubMed]
  18. Scheijen B, Meijers RWJ, Rijntjes J, Van der Klift MY, Mobs M, Steinhilber J et al (2019) Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia 33:2227–2240 doi: 10.1038/s41375-019-0508-7. [DOI] [PMC free article] [PubMed]
  19. Nadeu F, Mas-de-Les-Valls R, Navarro A, Royo R, Martin S, Villamor N et al (2020) IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. Nat Commun 11:3390 doi: 10.1038/s41467-020-17095-7. [DOI] [PMC free article] [PubMed]

RESOURCES